An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia
Latest Information Update: 10 Jan 2025
Price :
$35 *
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms CONTINUITY
- Sponsors AstraZeneca; AstraZeneca AB
- 08 Jan 2025 Status changed from active, no longer recruiting to completed.
- 25 Sep 2024 Planned End Date changed from 20 Dec 2024 to 16 Dec 2024.
- 25 Sep 2024 Planned primary completion date changed from 20 Dec 2024 to 16 Dec 2024.